Cargando…
Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
Introduction: Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. BRAF V600E mutation is detected in nearly all classical HCL cases which offers the possibility of targeted therapy. Objective: The aim of our study was to assess the efficacy of low-dose vemurafenib as well as...
Autores principales: | Ferenczi, Kata, Nagy, Zsófia Flóra, Istenes, Ildikó, Eid, Hanna, Bödör, Csaba, Timár, Botond, Demeter, Judit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663343/ https://www.ncbi.nlm.nih.gov/pubmed/38025907 http://dx.doi.org/10.3389/pore.2023.1611378 |
Ejemplares similares
-
Case Report: Development of Diffuse Large B Cell Lymphoma a Long Time After Hairy Cell Leukemia
por: Nagy, Zsófia F., et al.
Publicado: (2022) -
Correlations Between the Expression of Stromal Cell Activation Related Biomarkers, L-NGFR, Phospho-ERK1-2 and CXCL12, and Primary Myelofibrosis Progression
por: Szekely, Tamas, et al.
Publicado: (2022) -
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
por: Takács, Ferenc, et al.
Publicado: (2022) -
Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary
por: Kiss, Zoltan, et al.
Publicado: (2021) -
In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma
por: Mohás, Anna, et al.
Publicado: (2022)